Abstract
Effects of the tyrphostin tyrosine kinase inhibitor adaphostin (NSC 680410) have been examined in human leukemia cells (Jurkat, U937) in relation to mitochondrial events, apoptosis, and perturbations in signaling and cell cycle regulatory events. Exposure of cells to adaphostin concentrations ⩾0.75 μ M for intervals ⩾6 h resulted in a pronounced release of cytochrome c and AIF, activation of caspase-9, -8, and -3, and apoptosis. These events were accompanied by the caspase-independent downregulation of Raf-1, inactivation of MEK1/2, ERK, Akt, p70S6K, dephosphorylation of GSK-3, and activation of c-Jun-N-terminal kinase (JNK) and p38 MAPK. Adaphostin also induced cleavage and dephosphorylation of pRb on CDK2- and CDK4-specific sites, as well as the caspase-dependent downregulation of cyclin D1. Inducible expression of a constitutively active MEK1 construct markedly diminished adaphostin-induced cytochrome c and AIF release, JNK activation, and apoptosis in Jurkat cells. Ectopic expression of Raf-1 or constitutively activated (myristolated) Akt also significantly attenuated adaphostin-induced apoptosis, but protection was less than that conferred by enforced activation of MEK. Lastly, antioxidants (e.g., L-N-acetylcysteine; L-NAC) opposed adaphostin-mediated mitochondrial dysfunction, Raf-1/MEK/ERK downregulation, JNK activation, and apoptosis. However, in contrast to L-NAC, enforced activation of MEK failed to block adaphostin-mediated ROS generation. Together, these findings demonstrate that the tyrphostin adaphostin induces multiple perturbations in signal transduction pathways in human leukemia cells, particularly inactivation of the cytoprotective Raf-1/MEK/ERK and Akt cascades, that culminate in mitochondrial injury, caspase activation, and apoptosis. They also suggest that adaphostin-related oxidative stress acts upstream of perturbations in these signaling pathways to trigger the cell death process.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
Purchase on Springer Link
Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Allan LA, Morrice N, Brady S, Magee G, Pathak S and Clarke PR . (2003). Nat. Cell Biol., 5, 647–654.
Arguello F, Alexander M, Sterry JA, Tudor G, Smith EM, Kalavar NT, Greene Jr JF, Koss W, Morgan CD, Stinson SF, Siford TJ, Alvord WG, Klabansky RL and Sausville EA . (1998). Blood, 91, 2482–2490.
Avramis IA, Christodoulopoulos G, Suzuki A, Laug WE, Gonzalez-Gomez I, McNamara G, Sausville EA and Avramis VI . (2002). Cancer Chemother. Pharmacol., 50, 479–489.
Bonni A, Brunet A, West AE, Datta SR, Takasu MA and Greenberg ME . (1999). Science, 286, 1358–1362.
Carlson B, Lahusen T, Singh S, Loaiza-Perez A, Worland PJ, Pestell R, Albanese C, Sausville EA and Senderowicz AM . (1999). Cancer Res., 59, 4634–4641.
Chandra J, Hackbarth J, Le S, Loegering D, Bone N, Bruzek LM, Narayanan VL, Adjei AA, Kay NE, Tefferi A, Karp JE, Sausville EA and Kaufmann SH . (2003). Blood, [Epub ahead of print].
Chang F, Steelman LS, Lee JT, Shelton JG, Navolanic PM, Blalock WL, Franklin RA and McCubrey JA . (2003). Leukemia, 17, 1263–1293.
Chang L and Karin M . (2001). Nature, 410, 37–40.
Chau BN, Borges HL, Chen TT, Masselli A, Hunton IC and Wang JY . (2002). Nat. Cell Biol., 4, 757–765.
Clarke PA, Hostein I, Banerji U, Stefano FD, Maloney A, Walton M, Judson I and Workman P . (2000). Oncogene, 19, 4125–4133.
Dan S, Naito M and Tsuruo T . (1998). Cell Death Differ., 5, 710–715.
Datta SR, Brunet A and Greenberg ME . (1999). Genes Dev., 13, 2905–2927.
Franke TF, Kaplan DR and Cantley LC . (1997). Cell, 88, 435–437.
Hu Y, Qiao L, Wang S, Rong SB, Meuillet EJ, Berggren M, Gallegos A, Powis G and Kozikowski AP . (2000). J. Med. Chem., 43, 3045–3051.
Inoshita S, Takeda K, Hatai T, Terada Y, Sano M, Hata J, Umezawa A and Ichijo H . (2002). J. Biol. Chem., 277, 43730–43734.
Jarvis WD, Auer KL, Spector M, Kunos G, Grant S, Hylemon P, Mikkelsen R and Dent P . (1997). FEBS Lett., 412, 9–14.
Jia W, Yu C, Rahmani M, Krystal G, Sausville EA, Dent P and Grant S . (2003). Blood, 102, 1824–1832.
Johnson GL and Lapadat R . (2002). Science, 298, 1911–1912.
Kaur G, Gazit A, Levitzki A, Stowe E, Cooney DA and Sausville EA . (1994). Anticancer Drugs, 5, 213–222.
Kim AH, Khursigara G, Sun X, Franke TF and Chao MV . (2001). Mol. Cell. Biol., 21, 893–901.
Krystal GW, Honsawek S, Litz J and Buchdunger E . (2000). Clin. Cancer Res., 6, 3319–3326.
Lei K and Davis RJ . (2003). Proc. Natl. Acad. Sci. USA, 100, 2432–2437.
Levitzki A and Gazit A . (1995). Science, 267, 1782–1788.
Liu SX, Athar M, Lippai I, Waldren C and Hei TK . (2001). Proc. Natl. Acad. Sci. USA, 98, 1643–1648.
Milella M, Kornblau SM, Estrov Z, Carter BZ, Lapillonne H, Harris D, Konopleva M, Zhao S, Estey E and Andreeff M . (2001). J. Clin. Invest., 108, 851–859.
Moldeus P and Cotgreave IA . (1994). Methods Enzymol., 234, 482–492.
Muda M, Theodosiou A, Rodrigues N, Boschert U, Camps M, Gillieron C, Davies K, Ashworth A and Arkinstall S . (1996). J. Biol. Chem., 271, 27205–27208.
Pearson G, Robinson F, Beers Gibson T, Xu BE, Karandikar M, Berman K and Cobb MH . (2001). Endocr. Rev., 22, 153–183.
Platanias LC . (2003). Blood, 101, 4667–4679.
Scheid MP, Schubert KM and Duronio V . (1999). J. Biol. Chem., 274, 31108–31113.
Scheid MP and Woodgett JR . (2001). Nat. Rev. Mol. Cell. Biol., 2, 760–768.
Sebolt-Leopold JS, Dudley DT, Herrera R, Van Becelaere K, Wiland A, Gowan RC, Tecle H, Barrett SD, Bridges A, Przybranowski S, Leopold WR and Saltiel AR . (1999). Nat. Med., 5, 810–816.
Sparrow JR, Vollmer-Snarr HR, Zhou J, Jang YP, Jockusch S, Itagaki Y and Nakanishi K . (2003). J. Biol. Chem., 278, 18207–18213.
Svingen PA, Tefferi A, Kottke TJ, Kaur G, Narayanan VL, Sausville EA and Kaufmann SH . (2000). Clin. Cancer Res., 6, 237–249.
Tobiume K, Matsuzawa A, Takahashi T, Nishitoh H, Morita K, Takeda K, Minowa O, Miyazono K, Noda T and Ichijo H . (2001). EMBO Rep., 2, 222–228.
Tournier C, Hess P, Yang DD, Xu J, Turner TK, Nimnual A, Bar-Sagi D, Jones SN, Flavell RA and Davis RJ . (2000). Science, 288, 870–874.
Turner NA, Xia F, Azhar G, Zhang X, Liu L and Wei JY . (1998). J. Mol. Cell. Cardiol., 30, 1789–1801.
Wang X, Martindale JL, Liu Y and Holbrook NJ . (1998). Biochem. J., 333, 291–300.
Wennstrom S and Downward J . (1999). Mol. Cell. Biol., 19, 4279–4288.
Wolf G, Hannken T, Schroeder R, Zahner G, Ziyadeh FN and Stahl RA . (2001). FEBS Lett., 488, 154–159.
Wu CJ, O'Rourke DM, Feng GS, Johnson GR, Wang Q and Greene MI . (2001). Oncogene, 20, 6018–6025.
Xia Z, Dickens M, Raingeaud J, Davis RJ and Greenberg ME . (1995). Science, 270, 1326–1331.
Yamamoto K, Ichijo H and Korsmeyer SJ . (1999). Mol. Cell. Biol., 19, 8469–8478.
Yu C, Rahmani M, Dai Y, Conrad D, Krystal G, Dent P and Grant S . (2003a). Cancer Res., 63, 1822–1833.
Yu C, Rahmani M, Almenara J, Subler M, Krystal G, Conrad D, Varticovski L, Dent P and Grant S . (2003b). Cancer Res., 63, 2118–2126.
Yu C, Wang S, Dent P and Grant S . (2001). Mol. Pharmacol., 60, 143–154.
Acknowledgements
This work was supported by awards CA63753 and CA 93738 from the NIH, award 6045-03 from the Leukemia and Lymphoma Society of America, and award DAMD-17-03-1-0209 from the Department of Defense.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Yu, C., Rahmani, M., Almenara, J. et al. Induction of apoptosis in human leukemia cells by the tyrosine kinase inhibitor adaphostin proceeds through a RAF-1/MEK/ERK- and AKT-dependent process. Oncogene 23, 1364–1376 (2004). https://doi.org/10.1038/sj.onc.1207248
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1207248
Keywords
This article is cited by
-
Transcriptional drug repositioning and cheminformatics approach for differentiation therapy of leukaemia cells
Scientific Reports (2021)
-
Adaphostin toxicity in a sensitive non-small cell lung cancer model is mediated through Nrf2 signaling and heme oxygenase 1
Journal of Experimental & Clinical Cancer Research (2010)
-
ABT-737, a BH3 mimetic, induces glutathione depletion and oxidative stress
Cancer Chemotherapy and Pharmacology (2009)
-
Different target range and cytotoxic specificity of adaphostin and 17-allylamino-17-demethoxygeldanamycin in imatinib-resistant and sensitive cell lines
Leukemia (2007)
-
Adaphostin cytoxicity in glioblastoma cells is ROS-dependent and is accompanied by upregulation of heme oxygenase-1
Cancer Chemotherapy and Pharmacology (2007)